Tirzepatide vs semaglutide: what the trial data shows

Last updated 2026-07-27

What's the actual difference between tirzepatide and semaglutide?

Semaglutide is a GLP-1 receptor agonist. It mimics one gut hormone, GLP-1, that slows stomach emptying, curbs appetite signals in the brain, and boosts insulin release after meals. Tirzepatide does that too, but it also activates the GIP receptor, a second incretin hormone pathway. That's the whole pitch: two receptors instead of one. Whether dual-agonism is why tirzepatide edges out semaglutide in trials isn't fully settled. The GIP piece seems to help with insulin sensitivity and may blunt some of the nausea that comes with strong GLP-1 stimulation, but researchers are still arguing over exactly how much each receptor contributes to the weight loss seen in practice ^[1]. Brand names get confusing fast. Tirzepatide is sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), both made by Eli Lilly and both FDA-approved. Semaglutide is sold as Ozempic (diabetes) and Wegovy (weight), both made by Novo Nordisk. Compounded versions of both drugs exist outside the brand-name supply chain, made by state-licensed compounding pharmacies, and they are a different regulatory category entirely, not FDA-approved products in their own right.

How does tirzepatide's weight loss compare to semaglutide's in clinical trials?

The most-cited numbers come from separate trial programs, not a single head-to-head study in the same patients, so treat this as a strong signal, not a lab-controlled bake-off. In SURMOUNT-1 (NCT04184622), adults with obesity or overweight (without diabetes) lost an average of 15.0% of body weight on the 5 mg dose, 19.5% on 10 mg, and 20.9% on the 15 mg dose over 72 weeks, compared with 3.1% on placebo ^[1]. In STEP 1 (NCT03548935), adults on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks versus 2.4% on placebo ^[2]. There is one real head-to-head trial. SURMOUNT-5 (NCT05822830) directly compared tirzepatide against semaglutide 2.4 mg in adults with obesity, and tirzepatide produced significantly greater weight loss, with participants losing an average of about 20.2% of body weight versus about 13.7% on semaglutide over 72 weeks ^[3]. That's the closest thing to real evidence of tirzepatide's edge, since every other comparison mixes different trial populations and timeframes. | Trial | Drug | Dose | Avg. weight loss | Duration |

How do they compare for type 2 diabetes control?

Both drugs lower A1C meaningfully, and both are FDA-approved for type 2 diabetes under their respective brand names (Mounjaro for tirzepatide, Ozempic for semaglutide). In the SURPASS-2 trial (NCT03987919), tirzepatide was compared directly against semaglutide 1 mg (a lower dose than the 2.4 mg weight-management dose) in adults with type 2 diabetes. Tirzepatide at all three doses (5, 10, and 15 mg) reduced A1C more than semaglutide 1 mg, with mean A1C reductions ranging from about 2.01% to 2.30% for tirzepatide versus 1.86% for semaglutide, and greater body weight reduction as well ^[4]. That's the diabetes-specific head-to-head, and it's a real one, not a cross-trial guess. One caveat: SURPASS-2 used semaglutide 1 mg, not the 2 mg dose that's now more commonly prescribed for diabetes, so the comparison may understate what higher-dose semaglutide can do on A1C.

Which one has worse side effects?

Both drugs share a similar core side-effect profile: nausea, diarrhea, constipation, vomiting, and decreased appetite. These are GI-tract effects tied to slowed gastric emptying, and they show up with both GLP-1-only and dual-agonist drugs. In SURMOUNT-1, the most common adverse events were gastrointestinal, and were generally mild to moderate and occurred mostly during dose escalation ^[1]. In STEP 1, nausea (44.2%), diarrhea (30.4%), and vomiting (24.8%) were the most common adverse events reported with semaglutide over the trial, again concentrated in the dose-escalation period ^[2]. Discontinuation due to side effects was similar between the two drugs in these programs, generally in the single digits as a percentage of participants. Neither drug has shown a clearly worse GI tolerability profile than the other in trial data. Anecdotally, some patients report less nausea on tirzepatide, which may relate to the GIP component, but this isn't proven in head-to-head comparative data beyond SURMOUNT-5's overall tolerability findings. Getting the injection technique and site rotation right can reduce local site reactions and may help with overall tolerability. See Tirz Rx how to inject and Tirz Rx injection sites for practical guidance.

Do both drugs carry the same warnings and contraindications?

Yes, essentially. Both tirzepatide and semaglutide carry an FDA boxed warning for thyroid C-cell tumors seen in rodent studies. The label states these drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[5]. It is not known whether tirzepatide or semaglutide causes thyroid C-cell tumors in humans, but the signal from animal studies was strong enough that FDA required the warning on both drug classes. Both drugs also carry warnings for pancreatitis, and the Zepbound and Wegovy labels each note reports of acute pancreatitis during clinical trials, though a causal link isn't definitively established ^{[5] [6]}. Both labels warn about gallbladder problems (cholelithiasis, cholecystitis), which show up more often with rapid, substantial weight loss regardless of the drug causing it. Diabetic retinopathy complications have been flagged specifically with semaglutide in people with existing type 2 diabetes (seen in the SUSTAIN-6 cardiovascular outcomes trial), and both drugs warn about hypoglycemia risk when combined with insulin or sulfonylureas. Neither drug should be used during pregnancy, and both carry warnings about acute kidney injury (often secondary to dehydration from GI side effects) and hypersensitivity reactions.

How do the dosing schedules compare?

Semaglutide (Wegovy) starts at 0.25 mg weekly and titrates up over about 16-20 weeks to a maintenance dose of 2.4 mg weekly, with steps at 0.25, 0.5, 1, 1.7, and 2.4 mg ^[6]. Tirzepatide (Zepbound) starts at 2.5 mg weekly for four weeks, then increases in 2.5 mg increments every four weeks up to a maximum of 15 mg weekly ^[5]. Both are once-weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm. Neither requires daily dosing, which is one reason both classes displaced older daily GLP-1 drugs like liraglutide. For tirzepatide specifically, patients working with compounded formulations often need to reconstitute lyophilized powder themselves, a step brand-name pen users skip entirely. If you're doing that, walk through how to reconstitute Tirz Rx carefully, since dosing errors are more likely with a multi-step vial-and-syringe process than with a pre-filled pen. Cycle length and when to reassess also differ by individual response; see Tirz Rx cycle length for how that timeline typically plays out.

Is compounded tirzepatide the same as compounded semaglutide?

Both exist in the same regulatory gray zone, and both carry a similar basic risk profile: they are not FDA-approved products, meaning FDA has not verified their safety, effectiveness, or manufacturing quality the way it has for Zepbound, Mounjaro, Wegovy, or Ozempic. Compounded versions are legal under specific conditions, generally either because a drug is on the FDA drug shortage list (allowing 503A and 503B compounding under certain rules) or because a prescriber determines a patient needs a formulation change (like a different strength or an additive-free version) that isn't commercially available. FDA has published consumer guidance warning that some compounded semaglutide and tirzepatide products used salt forms (like semaglutide sodium or semaglutide acetate) that differ from the active ingredient in the FDA-approved drug, and that FDA "is aware of adverse event reports after patients used compounded semaglutide" including dosing errors from unclear vial concentrations ^[7]. As of 2025, both semaglutide and tirzepatide have come off FDA's drug shortage list in most formulations, which narrows the legal basis for mass-compounding either drug for patients who could instead get the brand-name product covered or paid for directly. Compounding for legitimate individualized medical need (documented allergies to an excipient, for example) remains legal, but the blanket shortage-based compounding that was common in 2023 and 2024 has largely ended for standard formulations.

Which drug costs less?

List prices for both brand-name products run high without insurance. Zepbound's list price is roughly $1,059 per month at standard maintenance doses, and Wegovy's list price is roughly $1,349 per month, though both companies have run direct cash-pay programs at lower prices for people paying out of pocket (Lilly's direct-to-consumer program has offered vials around $349-$499/month for certain Zepbound doses, and Novo Nordisk's NovoCare pharmacy has offered Wegovy around $499/month for cash-pay patients) . Actual out-of-pocket cost depends heavily on insurance coverage, which varies a lot by plan and whether the diagnosis is diabetes (better covered) versus weight management alone (frequently excluded). Compounded versions of either drug are typically cheaper than brand list price, but cost comparisons are apples-to-oranges given the different regulatory status, sourcing, and lack of FDA manufacturing oversight. Price alone shouldn't be the deciding factor between a legitimate prescribed pathway and one where the source, purity, and dosing accuracy aren't independently verified.

Which one works faster?

Both take a similar amount of time to show visible results, since both require dose titration over months before reaching maintenance strength. Trial data shows meaningful average weight loss differences between placebo and drug arms as early as 8-12 weeks in both SURMOUNT-1 and STEP 1 programs, but the biggest cumulative losses come from staying on a stable maintenance dose for 6 months or more. Neither drug is designed for fast results measured in days or a couple weeks. People expecting rapid change in the first month are usually still in the low-dose titration phase for both drugs, when weight loss is typically more modest than what maintenance dosing produces later.

Can you switch from semaglutide to tirzepatide (or vice versa)?

Yes, people do this, usually because of a plateau, side effects, or insurance formulary changes, but it should be done under medical guidance rather than as a self-directed swap. There isn't a large body of published trial data specifically studying the transition protocol (dose equivalency, washout period) between the two drugs, so most switching guidance in practice is based on general pharmacokinetic reasoning (both have multi-day half-lives, roughly 5 days for semaglutide and about 5 days for tirzepatide) rather than a dedicated switch-over trial. Many prescribers restart the new drug at its lowest titration dose rather than jumping to an equivalent higher dose, given the different receptor pharmacology and the risk of stacking GI side effects during any overlap. If you're considering a switch, that's a conversation for whoever is managing your prescription, not something to reason out from forum posts.

Which one should you actually choose?

If you're only weighing average trial outcomes, tirzepatide has the edge on weight loss magnitude, backed by the direct SURMOUNT-5 comparison ^[3] and the larger overall percentages in SURMOUNT-1 ^[1] compared to STEP 1 semaglutide data ^[2]. For type 2 diabetes, SURPASS-2 showed tirzepatide outperforming semaglutide 1 mg on A1C reduction too ^[4]. But trial averages aren't your personal outcome. Some people respond better to semaglutide, some tolerate tirzepatide's GI effects better (or worse), and insurance coverage or formulary restrictions often make the choice for you regardless of trial data. Cost, side-effect tolerance, and what your prescriber has experience managing all matter as much as the population averages above. A provider-reviewed evaluation, working with a licensed prescriber who reviews your health history and current medications, is the responsible way to decide between the two, rather than picking based on which one had a bigger headline number in a trial with a different patient population than you. Where tirzepatide is the right fit and a compounded pathway is medically appropriate, look for a route that includes provider review and a named, licensed pharmacy actually dispensing the medication, not an anonymous vial-only checkout.

Frequently asked questions

Is tirzepatide better than semaglutide for weight loss?

Trial data suggests tirzepatide produces somewhat greater average weight loss. The direct comparison trial SURMOUNT-5 (NCT05822830) found about 20.2% average weight loss with tirzepatide versus about 13.7% with semaglutide over 72 weeks. Individual response still varies a lot, and semaglutide works very well for many people.

What is the difference between Mounjaro, Zepbound, Ozempic, and Wegovy?

Mounjaro and Zepbound both contain tirzepatide, made by Eli Lilly; Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management. Ozempic and Wegovy both contain semaglutide, made by Novo Nordisk; Ozempic is approved for diabetes, Wegovy for weight management. Each pair shares one drug molecule but differs in approved use and sometimes max dose.

Does tirzepatide have more side effects than semaglutide?

No large trial has shown tirzepatide to have a clearly worse side-effect profile overall. Both cause similar rates of nausea, diarrhea, vomiting, and constipation, concentrated during dose escalation. SURMOUNT-5's tolerability data didn't show a major safety gap between the two drugs at comparable efficacy.

Can tirzepatide and semaglutide both cause thyroid cancer?

Both carry the same FDA boxed warning based on rodent studies showing thyroid C-cell tumors. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is not confirmed that either drug causes these tumors in humans, but FDA required the warning as a precaution on both drug labels.

Which drug is FDA-approved and which is compounded?

Both tirzepatide and semaglutide have FDA-approved brand-name versions (Mounjaro/Zepbound and Ozempic/Wegovy). Compounded versions of both also exist through licensed compounding pharmacies, but compounded products are not FDA-approved and are legal only under specific conditions, such as drug shortages or documented individual medical need.

How much weight can you lose on tirzepatide vs semaglutide in a year?

In SURMOUNT-1, average weight loss at 72 weeks reached 20.9% on the 15 mg tirzepatide dose. In STEP 1, average weight loss at 68 weeks was 14.9% on semaglutide 2.4 mg. These are trial averages from separate patient populations, so individual results vary.

Is tirzepatide or semaglutide better for type 2 diabetes?

The SURPASS-2 trial directly compared them in people with type 2 diabetes and found tirzepatide (5, 10, and 15 mg) reduced A1C by 2.01% to 2.30% versus 1.86% for semaglutide 1 mg, with tirzepatide also producing greater weight loss. Semaglutide was tested at a lower dose than the 2 mg used more commonly today.

Can you switch from semaglutide to tirzepatide?

Yes, this is done in practice, usually restarting tirzepatide at its lowest dose rather than an equivalent higher dose. There's no large published trial specifically studying the switch protocol between the two drugs, so timing and dosing during a transition should be managed by a prescriber, not self-directed.

Which costs less, tirzepatide or semaglutide?

List prices are similar and both are expensive without insurance: Zepbound lists around $1,059/month and Wegovy around $1,349/month, though both manufacturers run cash-pay programs at lower prices for uninsured patients. Actual cost depends heavily on insurance coverage and whether the prescription is for diabetes or weight management alone.

Do tirzepatide and semaglutide work the same way in the body?

Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors, which is why it's called a dual agonist. Both slow gastric emptying and reduce appetite; the added GIP activity in tirzepatide may account for some of its larger average effect on weight, though the exact mechanism split isn't fully settled.

Is compounded tirzepatide as safe as compounded semaglutide?

Both carry a similar basic regulatory risk: neither is FDA-approved as a compounded product, so manufacturing quality and exact dosing aren't independently verified the way brand-name drugs are. FDA has published warnings about adverse events and incorrect salt forms used in some compounded versions of both drugs.

How fast does tirzepatide work compared to semaglutide?

Both show measurable average weight loss differences from placebo within the first 8 to 12 weeks in trial data, but both require several months of dose titration before reaching maintenance strength. Neither drug is designed to produce fast results in the first few weeks; most of the total weight loss accumulates over 6 months or more.

Sources

1. NEJM, tirzepatide mechanism discussion (SURMOUNT-1 publication): Tirzepatide is a dual GIP/GLP-1 receptor agonist tested in SURMOUNT-1
2. NEJM, STEP 1 trial results (NCT03548935): STEP 1 semaglutide 2.4mg weight loss results at 68 weeks
3. ClinicalTrials.gov, SURMOUNT-5 (NCT05822830): Direct head-to-head trial of tirzepatide vs semaglutide 2.4mg for weight loss
4. NEJM, SURPASS-2 trial results (NCT03987919): Tirzepatide vs semaglutide 1mg A1C reduction in type 2 diabetes
5. FDA, Zepbound prescribing information: Boxed warning for thyroid C-cell tumors, MEN2/MTC contraindication, pancreatitis warning for tirzepatide
6. FDA, Wegovy prescribing information: Semaglutide dosing titration schedule and boxed warning/pancreatitis language
7. Eli Lilly, Zepbound self-pay pricing (LillyDirect): Zepbound list price and direct-to-consumer vial pricing